Tasca 1985.

Methods	Single‐site trial Randomization: noted, but method not stated Blinding: participants, providers
Participants	Geographic region: Italy Study setting: community N = 30 Baseline symptom score: NR Baseline prostate volume: NR Mean age (range): 61.5 (49 to 81) years Race: white Diagnostic criteria: stage I and II prostatic adenomas
Interventions	Control: matching placebo Treatment: PA109 (Permixon) 160 mg twice daily Study duration: 8 weeks Lost to follow‐up: 10%
Outcomes	Dysuria (% reporting) Peak urine flow Mean urine flow Total voided volume Pollakiuria ‐ daytime (% reporting) Pollakiuria ‐ nocturnal (% reporting) Urgency (% reporting) Dropouts due to side effects: 1 participant from the treatment group
Notes	Exclusions: details not provided Full text not available for this update.